Dr. Bobby Reddy, CMO at ImmunityBio, discusses the company's innovations in changing bladder cancer treatment standards, commercial readiness for Anktiva, physician engagement strategies, and global press outreach. The episode covers advancements in cancer therapy, regulatory team building, strategic drug production, and breakthroughs in cell-based therapies. It also explores challenges in biotech organization, collaborative efforts, and advice for aspiring CMOs.

Jason Gardner, CEO of Ampersand Biomedicines, discusses applying his biotech leadership experience to precision medicine, big data, AI, and company culture. He shares insights on the acquisition strategy, revolutionary drug delivery technology, navigating capital markets, and balancing paranoia with optimism as a CEO.

Karen Harris, CFO of ADDF, shares insights on funding Alzheimer's therapies and the value of venture philanthropy in biotech. She discusses the challenges in securing funding, the shift towards aging biology in treatments, and the investments in CNS-related work. The episode delves into the relationship between anti-aging research and neurodegenerative diseases, emphasizing the importance of Alzheimer's research and venture philanthropy in biotech funding.

Mike Nally from Generate:Biomedicines discusses the AI impact in biotech, emphasizing generative biology's work in drug discovery. Topics include exploring protein language for therapeutics, funding rounds, transformative AI impact, functional protein database, AI challenges in drug discovery, and navigating success and failure in the biotech industry.

Dr. Gavin Samuels shares his journey from intensive care physician to CINRX, discussing strategic deals, healthcare innovation, and alternative obesity treatments. The podcast explores efficient biotech services, successful professional attributes, and the importance of collaboration in the industry.

Rob Williamson discusses his successful career in biotech startups, focusing on Triumvira's innovative T-cell therapeutics in oncology. He shares insights on cancer therapeutics, dealmaking, and the future of the biotech industry.

We love to hear from our listeners. Send us a message. In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it. Despite an approach to developing antibodies and other biologics that looks decidedly different--they're developed from spirulina cell lines and, in some cases, designed for oral administration (gasp!)--Lumen Biosciences has won hard-fought funding from some nontraditional sources to continue its mission to democratize biologics. Finrow is Co-Founder & CEO at Lumen, and now a two-time guest of the Business of Biotech. He's a Harvard J.D., but don't hold that against him. He's one of the most approachable and transparent founders we've enjoyed the pleasure of hosting, and he didn't disappoint when we sat down for this talk in San Francisco. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

We love to hear from our listeners. Send us a message. Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necessary companion diagnostic arena. On today’s episode of the Business of Biotech, recorded in San Francisco, we sit down with Dr. Mark Hoppin, CEO of Ratio Therapeutics, a company that’s well-positioned in the space with a fresh Series B and the foundation of a tunable radiotherapeutic that Dr. Hoppin says addresses the delivery, safety and efficacy challenges long associated with radiopharmaceuticals in the treatment of solid cancers. We also discuss how this mathemetician-turned biotech CEO has navigated the leadership of boards, employees, and investors on his journey.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

We love to hear from our listeners. Send us a message. While you might be aware that Sail Biomedicines  was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume  Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic.  On this episode  of the Business of Biotech, Dr. Pfefer takes us under the hood of Sail Biomedicines and its mission to marry evolution and AI to develop programmable medicines based on eRNA.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

On this episode, Mark Kotter, CEO of Bit.bio, discusses the concept of programmable biology and the challenges involved in building capabilities. They delve into the interdisciplinary team required, the innovative cell reprogramming at Bit.bio, focusing on regenerative medicine indications, funding journey, stem cell reprogramming for aging interventions, and visibility in the biotech space.